Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew B Lassman

Showing results (41-50 of 145) with videos related to

Pageof 15
Sort By:
Nature Reviews. Clinical Oncology|July 5, 2017
Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cellsHui K Gan, Martin van den Bent, Andrew B Lassman, et al.
Cancer|November 5, 2005
Salvage temozolomide for prior temozolomide respondersEnrico Franceschi, Antonio M P Omuro, Andrew B Lassman, et al.
Journal of Neuro-Oncology|June 28, 2007
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomasGaurav D Shah, Joel S Silver, Steven S Rosenfeld, et al.
The Oncologist|October 12, 2018
Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A ReviewAlfred I Neugut, Paul Sackstein, Grace C Hillyer, et al.
Neurology|September 19, 2018
Clinical Reasoning: Transient speech deficits in a patient with history of medulloblastomaJessica D Schulte, Gunnar Hargus, Peter Canoll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy DeliveryAndrew B Lassman, Mei-Yin C Polley, Fabio M Iwamoto, et al.
Neuro-Oncology|August 26, 2011
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerChristian Grommes, Geoffrey R Oxnard, Mark G Kris, et al.
Journal of Neuro-Oncology|December 29, 2011
Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitorsSamuel A Goldlust, Robert Cavaliere, Herbert B Newton, et al.
Investigational New Drugs|May 22, 2020
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant gliomaDavid A Reardon, Annick Desjardins, Olivier Rixe, et al.
Journal of Neuro-Oncology|November 8, 2007
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastasesFabio M Iwamoto, Antonio M Omuro, Jeffrey J Raizer, et al.
Pageof 15

Showing results (41-50 of 145) with videos related to

Sort By:
Pageof 15
Nature Reviews. Clinical Oncology|July 5, 2017
Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cellsHui K Gan, Martin van den Bent, Andrew B Lassman, et al.
Cancer|November 5, 2005
Salvage temozolomide for prior temozolomide respondersEnrico Franceschi, Antonio M P Omuro, Andrew B Lassman, et al.
Journal of Neuro-Oncology|June 28, 2007
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomasGaurav D Shah, Joel S Silver, Steven S Rosenfeld, et al.
The Oncologist|October 12, 2018
Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A ReviewAlfred I Neugut, Paul Sackstein, Grace C Hillyer, et al.
Neurology|September 19, 2018
Clinical Reasoning: Transient speech deficits in a patient with history of medulloblastomaJessica D Schulte, Gunnar Hargus, Peter Canoll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy DeliveryAndrew B Lassman, Mei-Yin C Polley, Fabio M Iwamoto, et al.
Neuro-Oncology|August 26, 2011
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerChristian Grommes, Geoffrey R Oxnard, Mark G Kris, et al.
Journal of Neuro-Oncology|December 29, 2011
Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitorsSamuel A Goldlust, Robert Cavaliere, Herbert B Newton, et al.
Investigational New Drugs|May 22, 2020
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant gliomaDavid A Reardon, Annick Desjardins, Olivier Rixe, et al.
Journal of Neuro-Oncology|November 8, 2007
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastasesFabio M Iwamoto, Antonio M Omuro, Jeffrey J Raizer, et al.
Pageof 15